DNER and acute myeloid leukemia: In addition to the single-agent BET targeting that primarily inhibits the MYC expression [17], a combination of BET inhibitors with a second agent, such as the CDK9 inhibitor alvocidib, demonstrates a strong synergistic effect on suppressing AML [130].